Symbols / NGEN Stock $3.63 -3.20% NervGen Pharma Corp.

Healthcare • Biotechnology • Canada • NCM
NGEN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO —
Exch · Country NCM · Canada
Market Cap 293.78M
Enterprise Value 271.72M
Income -44.12M
Sales —
FCF (ttm) -6.29M
Book/sh 0.03
Cash/sh 0.27
Employees —
Insider 10d —
IPO Apr 03, 2019
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -9.57
PEG —
P/S —
P/B 112.87
P/C —
EV/EBITDA -10.86
EV/Sales —
Quick Ratio 1.12
Current Ratio 1.16
Debt/Eq 0.24
LT Debt/Eq —
EPS (ttm) -0.45
EPS next Y -0.38
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-14
Earnings (prior) 2026-03-31
ROA -73.42%
ROE -14.58%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 80.93M
Shs Float 68.91M
Insider Own 20.74%
Instit Own 0.51%
Short Float —
Short Ratio 5.82
Short Interest 1.43M
52W High 6.30
vs 52W High -42.38%
52W Low 1.50
vs 52W Low 142.00%
Beta 0.99
Impl. Vol. 25.00%
Rel Volume 1.26
Avg Volume 162.99K
Volume 205.07K
Target (mean) $10.39
Tgt Median $8.20
Tgt Low $5.03
Tgt High $18.00
# Analysts 7
Recom Buy
Prev Close $3.75
Price $3.63
Change -3.20%
About

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$10.39
Mean price target
2. Current target
$3.63
Latest analyst target
3. DCF / Fair value
$-1.40
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.63
Low
$5.03
High
$18.00
Mean
$10.39

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-27 init HC Wainwright & Co. — → Buy $18
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-08 Mckerracher (Krista L) Director of Issuer — 10,000 $4.19 $41,910
2026-04-02 Mckerracher (Krista L) Director of Issuer — 5,000 $4.23 $21,150
2026-03-02 Mckerracher (Krista L) Director of Issuer — 10,000 $3.85 $38,520
2026-02-26 Mckerracher (Krista L) Director of Issuer — 5,000 $4.13 $20,640
2026-02-26 Mckerracher (Krista L) Director of Issuer — 5,000 $4.10 $20,515
2026-02-20 Mckerracher (Krista L) Director of Issuer — 9,980 $4.30 $42,914
2026-02-19 Mckerracher (Krista L) Director of Issuer — 10,000 $4.18 $41,770
2026-02-19 Mckerracher (Krista L) Director of Issuer — 20 $4.30 $86
2026-02-18 Mckerracher (Krista L) Director of Issuer — 10,000 $3.02 $30,170
2026-02-12 Mckerracher (Krista L) Director of Issuer — 10,000 $4.00 $39,960
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
25.08
-0.38%
25.18
+41.62%
17.78
-22.79%
23.03
Research And Development
13.91
-12.04%
15.81
+96.50%
8.05
-51.57%
16.61
Selling General And Administration
11.17
+19.65%
9.34
-3.06%
9.63
+51.96%
6.34
General And Administrative Expense
11.17
+19.65%
9.34
-3.06%
9.63
+51.96%
6.34
Salaries And Wages
6.77
+1.17%
6.69
-1.11%
6.76
+106.42%
3.28
Other Gand A
4.41
+66.31%
2.65
-7.65%
2.87
-6.33%
3.06
Total Expenses
25.08
-0.38%
25.18
+41.62%
17.78
-22.79%
23.03
Operating Income
-25.08
+0.38%
-25.18
-41.62%
-17.78
+22.79%
-23.03
EBITDA
-25.02
+0.27%
-25.09
-42.31%
-17.63
+12.25%
-20.09
Normalized EBITDA
-5.65
+77.58%
-25.21
-102.03%
-12.48
+45.06%
-22.71
Reconciled Depreciation
0.06
-33.42%
0.08
-42.21%
0.15
+25.96%
0.12
EBIT
-25.08
+0.38%
-25.18
-41.62%
-17.78
+12.03%
-20.21
Total Unusual Items
-19.37
-17169.93%
0.11
+102.20%
-5.16
-297.08%
2.62
Total Unusual Items Excluding Goodwill
-19.37
-17169.93%
0.11
+102.20%
-5.16
-297.08%
2.62
Net Income
-44.12
-81.93%
-24.25
-8.35%
-22.38
-8.01%
-20.72
Pretax Income
-44.12
-81.93%
-24.25
-8.35%
-22.38
-8.01%
-20.72
Net Non Operating Interest Income Expense
0.33
-58.97%
0.81
+47.73%
0.55
+275.63%
-0.31
Interest Expense Non Operating
—
—
0.00
-100.00%
0.51
Net Interest Income
0.33
-58.97%
0.81
+47.73%
0.55
+275.63%
-0.31
Interest Expense
—
—
0.00
-100.00%
0.51
Interest Income Non Operating
0.33
-58.97%
0.81
+47.73%
0.55
+173.13%
0.20
Interest Income
0.33
-58.97%
0.81
+47.73%
0.55
+173.13%
0.20
Other Income Expense
-19.37
-17169.93%
0.11
+102.20%
-5.16
-297.08%
2.62
Gain On Sale Of Security
-19.37
-17169.93%
0.11
+102.20%
-5.16
-297.08%
2.62
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-44.12
-81.93%
-24.25
-8.35%
-22.38
-8.01%
-20.72
Net Income From Continuing Operation Net Minority Interest
-44.12
-81.93%
-24.25
-8.35%
-22.38
-8.01%
-20.72
Net Income From Continuing And Discontinued Operation
-44.12
-81.93%
-24.25
-8.35%
-22.38
-8.01%
-20.72
Net Income Continuous Operations
-44.12
-81.93%
-24.25
-8.35%
-22.38
-8.01%
-20.72
Normalized Income
-24.75
-1.57%
-24.36
-41.43%
-17.23
+26.19%
-23.34
Net Income Common Stockholders
-44.12
-81.93%
-24.25
-8.35%
-22.38
-8.01%
-20.72
Diluted EPS
—
-0.36
+5.26%
-0.38
+2.56%
-0.39
Basic EPS
—
-0.36
+5.26%
-0.38
+2.56%
-0.39
Basic Average Shares
—
67.32
+13.55%
59.29
+12.61%
52.65
Diluted Average Shares
—
67.32
+13.55%
59.29
+12.61%
52.65
Diluted NI Availto Com Stockholders
-44.12
-81.93%
-24.25
-8.35%
-22.38
-8.01%
-20.72
Depreciation Amortization Depletion Income Statement
0.00
-100.00%
0.03
-71.59%
0.10
+34.36%
0.07
Depreciation And Amortization In Income Statement
0.00
-100.00%
0.03
-71.59%
0.10
+34.36%
0.07
Depreciation Income Statement
0.00
-100.00%
0.03
-71.59%
0.10
+34.36%
0.07
Total Other Finance Cost
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
23.21
+19.11%
19.49
+47.22%
13.24
-44.56%
23.88
Current Assets
22.80
+19.92%
19.01
+51.91%
12.52
-45.93%
23.15
Cash Cash Equivalents And Short Term Investments
22.08
+27.14%
17.36
+48.93%
11.66
-48.07%
22.45
Cash And Cash Equivalents
22.07
+27.81%
17.27
+48.10%
11.66
-48.07%
22.45
Cash Financial
—
—
—
22.45
Other Short Term Investments
0.01
-91.39%
0.10
0.00
—
Receivables
0.08
-80.54%
0.42
+65.98%
0.25
+825.77%
0.03
Accounts Receivable
—
—
0.25
+825.77%
0.03
Other Receivables
0.03
-90.65%
0.27
+8.31%
0.25
—
Taxes Receivable
0.06
-61.63%
0.14
+43735.15%
0.00
—
Prepaid Assets
—
0.72
+21.64%
0.59
-12.02%
0.67
Current Deferred Assets
0.00
-100.00%
0.41
0.00
—
Other Current Assets
0.64
-22.00%
0.82
+4937.45%
0.02
—
Total Non Current Assets
0.41
-13.56%
0.47
-34.31%
0.72
-0.85%
0.73
Net PPE
0.00
0.00
-100.00%
0.20
-32.34%
0.30
Gross PPE
0.00
0.00
-100.00%
0.20
-32.34%
0.30
Other Properties
—
—
0.20
-32.34%
0.30
Goodwill And Other Intangible Assets
0.41
-12.00%
0.46
-10.71%
0.52
+20.71%
0.43
Other Intangible Assets
0.41
-12.00%
0.46
-10.71%
0.52
+20.71%
0.43
Investments And Advances
0.00
-100.00%
0.01
0.00
—
Other Investments
0.00
-100.00%
0.01
0.00
—
Total Liabilities Net Minority Interest
19.73
+16.70%
16.91
+10.92%
15.25
+46.39%
10.41
Current Liabilities
19.73
+16.75%
16.90
+11.64%
15.14
+48.18%
10.22
Payables And Accrued Expenses
3.29
-12.82%
3.78
+48.14%
2.55
-24.94%
3.40
Payables
0.03
-17.87%
0.03
-98.99%
3.32
+32.52%
2.51
Accounts Payable
—
—
3.32
+65.90%
2.00
Other Payable
0.03
-17.87%
0.03
—
—
Current Accrued Expenses
3.27
-12.77%
3.75
+46.83%
2.55
+185.92%
0.89
Pensionand Other Post Retirement Benefit Plans Current
1.36
+17.24%
1.16
+63.65%
0.71
—
Current Debt And Capital Lease Obligation
0.01
-91.39%
0.10
+6.17%
0.09
+6.17%
0.09
Current Capital Lease Obligation
0.01
-91.39%
0.10
+6.17%
0.09
+6.17%
0.09
Other Current Liabilities
15.07
+27.01%
11.86
+0.64%
11.79
+75.08%
6.73
Total Non Current Liabilities Net Minority Interest
0.00
-100.00%
0.01
-92.08%
0.11
-46.45%
0.20
Long Term Debt And Capital Lease Obligation
0.00
-100.00%
0.01
-92.08%
0.11
-46.45%
0.20
Long Term Capital Lease Obligation
0.00
-100.00%
0.01
-92.08%
0.11
-46.45%
0.20
Stockholders Equity
3.48
+34.94%
2.58
+228.25%
-2.01
-114.93%
13.46
Common Stock Equity
3.48
+34.94%
2.58
+228.25%
-2.01
-114.93%
13.46
Capital Stock
103.00
+26.85%
81.19
+37.78%
58.93
+2.65%
57.41
Common Stock
103.00
+26.85%
81.19
+37.78%
58.93
+2.65%
57.41
Share Issued
79.21
+12.62%
70.33
+18.00%
59.61
+1.41%
58.78
Ordinary Shares Number
79.21
+12.62%
70.33
+18.00%
59.61
+1.41%
58.78
Retained Earnings
-146.76
-42.98%
-102.65
-31.34%
-78.15
-40.13%
-55.77
Gains Losses Not Affecting Retained Earnings
47.24
+96.61%
24.03
+39.60%
17.21
+45.62%
11.82
Total Equity Gross Minority Interest
3.48
+34.94%
2.58
+228.25%
-2.01
-114.93%
13.46
Total Capitalization
3.48
+34.94%
2.58
+228.25%
-2.01
-114.93%
13.46
Working Capital
3.07
+45.28%
2.11
+180.47%
-2.62
-120.29%
12.93
Invested Capital
3.48
+34.94%
2.58
+228.25%
-2.01
-114.93%
13.46
Total Debt
0.01
-92.08%
0.11
-46.45%
0.20
-30.43%
0.28
Capital Lease Obligations
0.01
-92.08%
0.11
-46.45%
0.20
-30.43%
0.28
Net Tangible Assets
3.07
+45.28%
2.11
+183.47%
-2.53
-119.42%
13.03
Tangible Book Value
3.07
+45.28%
2.11
+183.47%
-2.53
-119.42%
13.03
Dueto Related Parties Current
—
—
0.44
-13.04%
0.50
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-19.50
-15.78%
-16.84
-49.09%
-11.30
+36.49%
-17.78
Cash Flow From Continuing Operating Activities
-19.50
-15.78%
-16.84
-49.09%
-11.30
+36.49%
-17.78
Net Income From Continuing Operations
-44.12
-81.93%
-24.25
-8.35%
-22.38
-8.01%
-20.72
Depreciation Amortization Depletion
0.06
-33.42%
0.08
-42.21%
0.15
+25.96%
0.12
Depreciation
0.00
-100.00%
0.03
-71.59%
0.10
+34.36%
0.07
Amortization Cash Flow
0.06
+0.00%
0.06
+20.17%
0.05
+11.21%
0.04
Depreciation And Amortization
0.06
-33.42%
0.08
-42.21%
0.15
+25.96%
0.12
Amortization Of Intangibles
0.06
+0.00%
0.06
+20.17%
0.05
+11.21%
0.04
Other Non Cash Items
—
0.01
-33.22%
0.01
-97.23%
0.53
Stock Based Compensation
5.39
-10.68%
6.04
-0.08%
6.04
+117.83%
2.77
Operating Gains Losses
18.51
+4134.26%
0.44
-91.47%
5.12
+297.34%
-2.60
Gain Loss On Investment Securities
18.96
+13846.90%
0.14
-97.28%
4.99
+361.59%
-1.91
Net Foreign Currency Exchange Gain Loss
-0.45
-253.61%
0.29
+129.87%
0.13
+118.65%
-0.69
Gain Loss On Sale Of PPE
0.00
-100.00%
0.01
0.00
—
Change In Working Capital
0.66
-21.60%
0.84
+448.89%
-0.24
-111.36%
2.11
Change In Receivables
0.33
+302.60%
-0.17
+26.03%
-0.22
-703.60%
0.04
Changes In Account Receivables
—
-0.17
+26.03%
-0.22
-703.60%
0.04
Change In Prepaid Assets
0.59
+364.25%
-0.22
-490.31%
0.06
+123.65%
-0.24
Change In Payables And Accrued Expense
-0.27
-121.85%
1.23
+1747.76%
-0.07
-103.21%
2.32
Change In Payable
—
—
—
2.32
Change In Account Payable
—
—
—
2.32
Investing Cash Flow
0.10
+71.43%
0.06
+142.40%
-0.14
-557.92%
-0.02
Cash Flow From Continuing Investing Activities
0.10
+71.43%
0.06
+142.40%
-0.14
-557.92%
-0.02
Net PPE Purchase And Sale
—
0.00
+100.00%
-0.00
+85.43%
-0.02
Purchase Of PPE
—
0.00
+100.00%
-0.01
+73.36%
-0.02
Sale Of PPE
—
0.00
-100.00%
0.00
0.00
Capital Expenditure
—
—
-0.14
-570.00%
-0.02
Net Intangibles Purchase And Sale
0.10
+71.43%
0.06
+143.36%
-0.14
0.00
Purchase Of Intangibles
—
0.00
+100.00%
-0.14
0.00
Financing Cash Flow
23.76
+4.71%
22.70
+2861.71%
0.77
-96.62%
22.64
Cash Flow From Continuing Financing Activities
23.76
+4.71%
22.70
+2861.71%
0.77
-96.62%
22.64
Net Issuance Payments Of Debt
-0.10
+0.00%
-0.10
+0.00%
-0.10
-33.33%
-0.08
Repayment Of Debt
-0.10
+0.00%
-0.10
+0.00%
-0.10
-33.33%
-0.08
Long Term Debt Payments
-0.10
+0.00%
-0.10
+0.00%
-0.10
-33.33%
-0.08
Net Long Term Debt Issuance
-0.10
+0.00%
-0.10
+0.00%
-0.10
-33.33%
-0.08
Net Common Stock Issuance
16.88
-26.63%
23.01
0.00
-100.00%
19.76
Proceeds From Stock Option Exercised
7.87
+456.56%
1.41
+63.12%
0.87
-71.87%
3.08
Net Other Financing Charges
-0.89
+45.24%
-1.63
—
-0.13
Changes In Cash
4.37
-26.17%
5.91
+155.43%
-10.67
-320.59%
4.84
Effect Of Exchange Rate Changes
0.44
+243.11%
-0.31
-146.19%
-0.12
-118.04%
0.69
Beginning Cash Position
17.27
+48.10%
11.66
-48.07%
22.45
+32.62%
16.93
End Cash Position
22.07
+27.81%
17.27
+48.10%
11.66
-48.07%
22.45
Free Cash Flow
-19.50
-15.78%
-16.84
-47.25%
-11.44
+35.77%
-17.81
Interest Paid Supplemental Data
0.00
0.00
0.00
0.00
Common Stock Issuance
16.88
-26.63%
23.01
0.00
-100.00%
19.76
Issuance Of Capital Stock
16.88
-26.63%
23.01
0.00
-100.00%
19.76
Sale Of Intangibles
0.10
+71.43%
0.06
0.00
—
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category